Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 276 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: mutation analysis Clear all
Recruiting No phase listed Observational

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

NCT04557969
View directory record Official record
Conditions
Gastric Cancer, Gastric Neoplasm, Gastrointestinal Stromal Sarcoma, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor (GIST)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

NCT01093573
View directory record Official record
Conditions
Untreated Adult Acute Myeloid Leukemia
Interventions
midostaurin, azacitidine, bone marrow aspiration, mutation analysis, Pharmacokinetic study
Drug · Other
Lead sponsor
Brenda Cooper, MD
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Cleveland, Ohio • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

NCT01532089
View directory record Official record
Conditions
EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Bevacizumab, Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
19
States / cities
La Jolla, California • Decatur, Illinois • Peoria, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Results available

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

NCT02508532
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors
Interventions
Avapritinib
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
9
States / cities
Scottsdale, Arizona • Santa Monica, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting Phase 2 Interventional

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

NCT03191149
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
347
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 238 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

NCT02152995
View directory record Official record
Conditions
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
Interventions
Computed Tomography, Iodine I 124, Iodine I-131, Laboratory Biomarker Analysis, Pharmacodynamic Study, Positron Emission Tomography, Trametinib
Procedure · Other · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Terminated Phase 1 Interventional

Next Generation Personalized Neuroblastoma Therapy

NCT02780128
View directory record Official record
Conditions
Neuroblastoma, Cancer
Interventions
Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib
Procedure · Genetic · Other + 2 more
Lead sponsor
Yael P Mosse
Other
Eligibility
1 Year to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Active, not recruiting Phase 2 Interventional

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

NCT02286687
View directory record Official record
Conditions
Advanced Malignant Neoplasm, ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Metastatic Malignant Neoplasm, PALB2 Gene Mutation, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational

Genetic Analysis of Immune Disorders

NCT00001467
View directory record Official record
Conditions
DOK 8, STAT1, GATA2, Immunodeficiency, STAT3
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 101 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting Phase 1 Interventional

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

NCT07089641
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Enasidenib in People With T-Cell Lymphoma

NCT06756308
View directory record Official record
Conditions
T-cell Lymphoma
Interventions
Enasidenib, Rituximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Withdrawn No phase listed Observational

Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer

NCT00897143
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
microarray analysis, mutation analysis, flow cytometry, immunologic technique
Genetic · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biomarkers in Friedreich's Ataxia

NCT02497534
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
6 Years to 70 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting Phase 2 Interventional

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

NCT05806515
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Surgical Procedure
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
133
States / cities
Anchorage, Alaska • Phoenix, Arizona • Arroyo Grande, California + 96 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor

NCT00006342
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma
Interventions
chromosomal translocation analysis, gene rearrangement analysis, mutation analysis
Genetic
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational

Detection of Genetic Markers of Lung Cancer

NCT00280202
View directory record Official record
Conditions
Lung Cancer
Interventions
Biopsy of the major carinal area, Biopsy of abnormal & suspicious areas of the bronchial tree, Evaluation of the tumor for DNA mutations, Bronchoalveolar Lavage (BAL) for cytokine analysis, Correlation of flow cytometric & RT PCR for TNM stage, Analysis of lymph nodes
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2050
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Investigating Age-Related Macular Degeneration

NCT00342251
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

NCT05919108
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
Interventions
Endocrine Therapy, Biopsy of breast, Neratinib, Biospecimen Collection, Mammogram, Magnetic Resonance Imaging, Breast Surgery, Ultrasound
Procedure · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
5
States / cities
Atlanta, Georgia • Pittsburgh, Pennsylvania • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational

Localized Leiomyosarcoma Biomarker Protocol

NCT04925089
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Blood and Tissue collection
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Study of Blood Samples From Newborns With Down Syndrome

NCT00959283
View directory record Official record
Conditions
Myeloid Proliferations Associated With Down Syndrome
Interventions
Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 90 Days
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
173
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 130 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting Not applicable Interventional

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

NCT05281731
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Sonobiopsy, Research blood, Cancer Personalized Profiling, Definity®
Device · Procedure · Genetic
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Terminated Phase 1 Interventional

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

NCT05388877
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Central Nervous System, Metastatic Melanoma
Interventions
Dabrafenib, MEK-1/MEKK-1 Inhibitor E6201, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

NCT01050504
View directory record Official record
Conditions
Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Recurrent Bladder Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

NCT05689021
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Prednisone
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 17, 2026, 5:14 AM EDT